...lower court ruling that definitively invalidates Amarin's fish oil derivative drug Vascepa's patents, meaning generic challengers can move forward. Amarin had blockbuster hopes for the heart drug, which the FDA approved in December 2019. Vascepa currently holds preferred status for 21% of all covered lives under the pharmacy benefit, growing to 44% with utilization management restrictions.
SOURCE: MMIT Analytics, as of 9/9/20
No comments:
Post a Comment